<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03858049</url>
  </required_header>
  <id_info>
    <org_study_id>MS200113_0005</org_study_id>
    <nct_id>NCT03858049</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Crinone Versus Combination Medication</brief_title>
  <acronym>ACCESS</acronym>
  <official_title>Comparison of Crinone Â® Versus Combination Medication for Luteal Phase Support on the Ongoing Pregnancy Rate of Frozen-thawed Cycle in Chinese Population a Randomized, Interventional, Open-label, Phase IV, Single Center, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Serono Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study to compare to the efficacy and safety of Crinone versus combination medication in
      infertile women receive frozen-thawed embryo transfer (FET) in artificial cycles (AC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing Pregnancy Rate</measure>
    <time_frame>8 to 10 weeks after embryo transfer</time_frame>
    <description>Ongoing pregnancy will be assessed by the presence of viable intra uterine fetus detected by ultrasound examination in 10-12 weeks of pregnancy. Ongoing pregnancy rate is defined as the number of ongoing pregnancies expressed per 100 embryo transfer cycles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta Human Chorionic Gonadotrophin (Beta-hCG) Positive Rate</measure>
    <time_frame>Day 14</time_frame>
    <description>Beta-hCG positive rate defined as the number of Beta-hCG positive participants expressed per 100 embryo transfer cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation Rate</measure>
    <time_frame>Day 35</time_frame>
    <description>The number of gestational sacs observed in ultrasound scan divided by the number of embryos transferred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy rate</measure>
    <time_frame>Day 35</time_frame>
    <description>A pregnancy diagnosed by ultrasound of one or more gestational sacs or definitive clinical signs of pregnancy. Clinical Pregnancy rate defined as the number of clinical pregnancies expressed per 100 embryo transfer cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Early Abortion</measure>
    <time_frame>Up to 12 Weeks</time_frame>
    <description>Early abortion defined as the spontaneous loss of an intra-uterine pregnancy prior to 12 completed weeks of gestational age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Luteal Phase Bleeding Rate</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Luteal Phase Bleeding defined as the onset of any bleeding after embryo transfer and prior to the pregnancy test. Luteal Phase Bleeding Rate defined as the number of the participants with luteal phase bleeding expressed per 100 embryos transferred cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal Bleeding Rate</measure>
    <time_frame>Day 14 to Day 63</time_frame>
    <description>Vaginal bleeding is defined as any bleeding recorded after a pregnancy test via serum Beta-Human Chorionic Gonadotrophin. Vaginal bleeding rate defined as the number of the participants with vaginal bleeding expressed per 100 embryos transferred cycles.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Crinone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Crinone plus Duphaston</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crinone</intervention_name>
    <description>Participants will receive 90 milligram (mg) of intravaginal Crinone gel daily in the morning in the treatment period for approximately 75 days.</description>
    <arm_group_label>Crinone</arm_group_label>
    <arm_group_label>Crinone plus Duphaston</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duphaston</intervention_name>
    <description>Participants will receive 10 mg of Duphaston orally twice a day in the treatment period for approximately 70 days.</description>
    <arm_group_label>Crinone plus Duphaston</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants are eligible to be included in the study only if all the following criteria
        apply:

          -  Participants who will receive artificial frozen-thawed embryo transfer (FET) cycle
             study interventions

          -  Participants who have no more than two Day 5 embryos are planned to be transferred
             (follow the clinical practice of the study site)

          -  Participants have received estradiol valerate for no more than 20 days

          -  Participants have a transitional-endometrium of greater than or equal to 8 millimeter

          -  Participants have normal uterine cavity

          -  Participants can give signed informed consent

          -  Participants are willing to follow the study protocol and able to complete the study

        Exclusion Criteria:

          -  Participants are willing to follow the study protocol and able to complete the study

          -  Participants with greater than or equal to three previously failed cycles of ET

          -  Participants with diseases that cannot tolerate pregnancy

          -  Hydrosalpinx

          -  Severe endometriosis (Endometriosis American Society for Reproductive Medicine (ASRM)
             criteria from 1996)

          -  Known hypersensitivity to progesterone, the excipients of Crinone and Duphaston
             Vaginal bleeding of unknown origin

          -  History of recurrent miscarriages

          -  Vaginitis

          -  Thromboembolic diseases (thrombophlebitis, thromboembolic disorder, or cerebral
             apoplexy) or participants with a history of these conditions

          -  Known or suspected progestogen-dependent neoplasm

          -  Participation in another clinical trial within the past 30 days

          -  Contraindications of both Crinone and Duphaston
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Qiao</last_name>
      <phone>+86(010)8 22 66 69</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200113_0005</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Frozen-thawed embryo transfer</keyword>
  <keyword>Infertility</keyword>
  <keyword>Crinone</keyword>
  <keyword>Duphaston</keyword>
  <keyword>Chinese population</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, Merck KGaA, Darmstadt, Germany, will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

